Fremont, Calif.-based proteomics diagnostics firm Vermillion announced this week that the European Patent Office has issued a decision to grant it a patent covering its use of biomarkers for the detection of ovarian cancer.

The patent, entitled "Use of Biomarkers for Detecting Ovarian Cancer," marks a significant step in the company's efforts to commercialize its OVA1 ovarian cancer protein biomarker test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.